Xiangxue Pharmaceutical

Corporate brand

A Chinese pharmaceutical company focused on traditional Chinese medicine, healthcare products, and related biotechnology.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Xiangxue Pharmaceutical Co., Ltd., also known as XPH, is a Chinese pharmaceutical company associated with the Luogang area of Guangzhou, Guangdong. The company takes its name from Luogang Xiangxue, a local scenic area whose name can be translated as “Fragrant Snow.” Its historical roots extend to Luogang Pharmaceutical, an enterprise established in 1958. Xiangxue Pharmaceutical itself was established on April 30, 1986, and was reorganized as a company limited by shares on December 29, 1997. Its shares began trading on the ChiNext board of the Shenzhen Stock Exchange on December 15, 2010, under ticker 300147.SZ. The company’s core business is centered on the research, manufacture, and sale of pharmaceutical products, particularly traditional Chinese medicine and modernized traditional Chinese medicine preparations. Publicly associated products include antiviral oral liquid and Banlangen granules, as well as Chinese medicinal materials and related healthcare products. The company has also operated in adjacent consumer and health categories, including herbal tea, soft drinks, and dietary or health supplements. This broader portfolio reflects an effort to connect pharmaceutical manufacturing with traditional remedies, wellness consumption, and healthcare-related commercial activities. Xiangxue’s product and revenue mix has included several distinct business areas. Information reported from its 2016 annual report attributed 29.60% of revenue to medicine manufacturing and 26.45% to medicine trading. Chinese medicine accounted for a further 32.94%, while soft drinks contributed 4.91%; medical equipment and other activities made up the remainder. These figures indicate that the company was not exclusively a finished-drug manufacturer, but also participated in medicine distribution, Chinese medicine processing or trading, and selected non-pharmaceutical businesses. One of its best-known consumer initiatives was Eisiti Herbal Tea, marketed in Chinese as Shangqingyin Liangcha. Eisiti competed in the Guangdong herbal-tea market against products associated with Wong Lo Kat and Jiaduobao. Reports stated that Eisiti production was suspended in 2011, although the company disputed or denied aspects of that reporting. Xiangxue has also been connected with the Asia soft-drink brand through a licensing arrangement involving an investment vehicle of the Guangzhou government, and with the Jochi health-supplement brand. The company has pursued biotechnology and innovative medicine in addition to traditional Chinese medicine. A publicly described collaboration with American biotechnology company Athenex involved development of T-cell receptor-engineered T-cell, or TCR-T, cancer immunotherapy. The initiative represented an attempt to move beyond conventional Chinese medicine and participate in advanced cell-therapy research. Xiangxue has maintained a visible regional marketing presence through sports sponsorships, especially football. It sponsored Guangzhou F.C. during the 2002–03 season, supported Guangdong Mingfeng in Hong Kong football competition, sponsored Sun Hei SC from 2005–06 through 2006–07, and was associated with Shenzhen F.C. in 2007 and 2008. During the Shenzhen sponsorship period, the club used Xiangxue and Eisiti naming elements. The company also held naming rights for the 2003–04 Hong Kong First Division League and the 2008–09 Hong Kong Senior Challenge Shield. On the capital-markets side, Xiangxue was formerly included in the Shenzhen Stock Exchange 200 Index and the SZSE Component Index. It was removed from the SZSE 200 Index in January 2017 and placed in the SZSE 700 Index, and was removed from the SZSE Component Index in July 2017. These index changes reflect market-index reclassification rather than a change in the company’s operating identity. Available reference material does not establish a current controlling parent company, a current chief executive, or a definitive present-day product mix. Accordingly, those fields r…

History

Xiangxue Pharmaceutical’s institutional history reaches back to Luogang Pharmaceutical, which was established in 1958 in the Luogang area of Guangzhou. The later Xiangxue Pharmaceutical enterprise was established on April 30, 1986. Its name refers to Luogang Xiangxue, a well-known local scenic area, and links the company’s identity to its Guangzhou origins. On December 29, 1997, the enterprise became a company limited by shares, a corporate form broadly comparable to a public limited company. The company subsequently developed as a pharmaceutical and traditional-Chinese-medicine business. Its activities included research and development, manufacturing, medicine trading, and the processing or sale of Chinese medicinal products. Its portfolio was not confined to one dosage form: public references associate Xiangxue with antiviral oral liquid, Banlangen granules, Chinese patent medicines, Chinese medicinal materials, and other traditional Chinese medicine products. The company also entered adjacent consumer-health categories, including herbal tea, soft drinks, and health supplements. Xiangxue’s consumer businesses included the Eisiti Herbal Tea brand, known in Chinese as Shangqingyin Liangcha. Eisiti competed in the southern Chinese herbal-tea market against Wong Lo Kat and Jiaduobao. Reports in 2011 said that production had been suspended, while the company rejected or challenged the characterization. The company was also connected with the Asia soft-drink brand through a licensing arrangement and marketed Jochi health supplements. These activities illustrate the company’s historical attempt to extend traditional health concepts into packaged beverages and consumer wellness products. The company became a listed enterprise when its shares started trading on the ChiNext board of the Shenzhen Stock Exchange on December 15, 2010, using stock code 300147.SZ. Its disclosed business mix later showed a combination of medicine manufacturing, medicine trading, Chinese medicine, soft drinks, medical equipment, and other activities. In the 2016 annual-report information cited by reference material, manufacturing medicine represented 29.60% of revenue, medicine trading 26.45%, Chinese medicine 32.94%, and soft drinks 4.91%. These figures describe the company’s historical mix and should not be treated as current financial data. Xiangxue also pursued advanced biotechnology. Its reported cooperation with Athenex focused on TCR-T cancer immunotherapy, in which T cells are engineered using cancer-targeting T-cell receptors. This project reflected an expansion from traditional Chinese medicine and conventional pharmaceutical products toward innovative cell-therapy research. Brand visibility was supported by regional sports sponsorships. Xiangxue sponsored Guangzhou F.C. in the 2002–03 season and was involved with Guangdong Mingfeng, a Zhaoqing-based youth or football organization that competed in Hong Kong. It later sponsored Sun Hei SC in Hong Kong and Shenzhen F.C.; during the Shenzhen relationship, the club used Xiangxue and Eisiti in its name. Xiangxue also obtained naming rights for the 2003–04 Hong Kong First Division League and the 2008–09 Hong Kong Senior Challenge Shield. In stock-index history, Xiangxue was once included in the SZSE 200 Index and the SZSE Component Index. It moved from the SZSE 200 to the SZSE 700 in January 2017 and left the SZSE Component Index in July of that year. Reference material does not provide enough verified information to identify current executives, a current parent company, or the company’s present operating scope with confidence. The brand should therefore be understood primarily through its documented history as a Guangzhou-based listed pharmaceutical and traditional-Chinese-medicine company.

2017
Index reclassification
[1]Xiangxue Pharmaceutical - Wikipediaen.wikipedia.org
Xiangxue leaves the SZSE 200 Index for the SZSE 700 Index in January and is removed from the SZSE Component Index in July.
2011
Eisiti production dispute
[1]Xiangxue Pharmaceutical - Wikipediaen.wikipedia.org
Reports state that Eisiti Herbal Tea production was suspended, while Xiangxue disputed or denied the report.
2010
ChiNext listing
[1]Xiangxue Pharmaceutical - Wikipediaen.wikipedia.org
The company’s shares begin trading on the ChiNext board of the Shenzhen Stock Exchange under code 300147 on December 15, 2010.
1997
Becomes a company limited by shares
[1]Xiangxue Pharmaceutical - Wikipediaen.wikipedia.org
Xiangxue is reorganized as a company limited by shares on December 29, 1997.
1986
Xiangxue Pharmaceutical is established
[1]Xiangxue Pharmaceutical - Wikipediaen.wikipedia.org
The Xiangxue Pharmaceutical enterprise is established on April 30, 1986.
1958
Luogang Pharmaceutical is established
[1]Xiangxue Pharmaceutical - Wikipediaen.wikipedia.org
Luogang Pharmaceutical, identified as the precursor to Xiangxue Pharmaceutical, is established in the Luogang area of Guangzhou.

Products and positioning

A Chinese pharmaceutical and traditional-Chinese-medicine company combining medicines, Chinese medicinal products, healthcare goods, and selected biotechnology initiatives.

Traditional Chinese medicine preparation
Antiviral oral liquid
An oral liquid positioned within Xiangxue’s traditional Chinese medicine and respiratory-health portfolio. It is one of the products most closely associated with the company in public descriptions.
Traditional Chinese medicine preparation
Banlangen granules
Granulated Chinese medicine based on Banlangen, a widely used traditional medicinal ingredient. The product is identified as one of Xiangxue’s representative offerings.
Herbal beverage
Eisiti Herbal Tea
A packaged herbal-tea product marketed under the Eisiti name, also rendered as Shangqingyin Liangcha in Chinese. It competed with major Guangdong herbal-tea brands, but its production status became disputed after reports of a suspension in 2011.
Soft drinks
Asia soft drinks
Soft drinks associated with the Asia brand through a licensing relationship involving an investment vehicle of the Guangzhou government. Soft drinks represented a minor component of the company’s reported 2016 revenue mix.
Health supplement
Jochi
A health-supplement brand associated with Xiangxue’s consumer-health activities. Available reference material identifies the brand but does not provide a detailed product catalogue or current distribution status.
Cell therapy research
TCR-T cancer immunotherapy
An oncology research program pursued with Athenex involving T-cell receptor-engineered T cells. The program represents Xiangxue’s documented interest in advanced cancer immunotherapy beyond traditional Chinese medicine.

Controversies

2025
Source
2025
Source

2008Hong Kong Senior Challenge Shield naming rights
Hong Kong
Xiangxue secured naming rights for the 2008–09 Hong Kong Senior Challenge Shield.
Outcome. The naming-rights arrangement covered the 2008–09 competition.
Source
2007Shenzhen F.C. sponsorship
China · Hong Kong
Xiangxue sponsored Shenzhen F.C. in 2007 and 2008. The club used Xiangxue and Eisiti naming elements during the relationship, and the club’s reserve side also used Xiangxue Eisiti in Hong Kong competition during 2008–09.
Outcome. The sponsorship was associated with the 2007 and 2008 seasons.
Source
2005Sun Hei SC sponsorship
Hong Kong
Xiangxue sponsored Hong Kong football club Sun Hei SC during the 2005–06 and 2006–07 seasons.
Outcome. The sponsorship concluded after the 2006–07 season.
Source
2003Hong Kong First Division League naming rights
Hong Kong
Xiangxue secured naming rights for the 2003–04 Hong Kong First Division League.
Outcome. The naming-rights period covered the 2003–04 season.
Source
2002Guangzhou F.C. sponsorship
China
Xiangxue sponsored Guangzhou F.C. during the 2002–03 season, linking the pharmaceutical brand with professional football in Guangzhou.
Outcome. The sponsorship ended after the 2002–03 season; later sponsorship arrangements involved other organizations and clubs.
Source
2001Guangdong Mingfeng football sponsorship
China · Hong Kong
Xiangxue sponsored Guangdong Mingfeng, a football team based in Zhaoqing, Guangdong, for the 2001–02 Hong Kong First Division League season.
Outcome. The arrangement was followed by other team and naming-rights relationships in Hong Kong and southern China.
Source

Brand decisions

2011
Response to reported Eisiti production suspensionStrategy
Background
Media reports stated that production of Eisiti Herbal Tea had been suspended.
Action taken
Xiangxue disputed or denied the reported suspension, according to the available reference material.
Aftermath
The product’s subsequent status is not established by the supplied sources.
Source
2010
List on the ChiNext boardOther
Background
Xiangxue pursued a public-market listing as part of its corporate development.
Action taken
Its shares began trading on the Shenzhen Stock Exchange’s ChiNext board on December 15, 2010, under code 300147.
Aftermath
The listing made Xiangxue a publicly traded Shenzhen-listed pharmaceutical company.
Source
Collaboration on TCR-T cancer immunotherapyProduct launch
Background
Xiangxue sought to extend its pharmaceutical activities into advanced oncology and cell-therapy research.
Action taken
The company worked with Athenex on T-cell receptor-engineered T-cell cancer immunotherapy.
Aftermath
The supplied material does not establish whether the therapy reached clinical commercialization.
Source

Sources9 sources

Cite this profile: Cite the canonical profile. /brand-wiki/xiangxue-pharmaceutical · Editorial policy · How profiles are compiled